Skip to content
Yog Pharma
8 minute read

How FDA's nitrosamine guidance applies to drug substances, which APIs carry higher risk, and the documents an API supplier should provide.

In 2018, N-nitrosodimethylamine (NDMA) was found in valsartan from several manufacturers, and recalls spread across the sartan class. Ranitidine followed, and was withdrawn from the US market in 2020. Extended-release metformin and other products were recalled after that. Nitrosamines are now a standing part of every API qualification, and the drug substance is where the assessment starts.

What FDA expects

FDA’s guidance on the control of nitrosamine impurities in human drugs asks manufacturers to work through three steps:

  1. Assess the risk of nitrosamines forming in, or contaminating, the API and the drug product.
  2. Run confirmatory testing with sensitive, validated methods where a risk is identified.
  3. Change the process, and report the change, where testing shows nitrosamines above acceptable limits.

Since 2023 FDA has also published recommended acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs), using a carcinogenic potency categorization approach that places each NDSRI in one of five categories with its own daily limit.

Where nitrosamines come from in an API

Nitrosamines form when a secondary or tertiary amine meets a nitrosating agent, such as nitrite, under the right conditions. In API manufacturing the usual sources are:

  • Reagents that contain or generate nitrite, such as sodium nitrite used to quench azide in tetrazole formation
  • Amine-containing solvents and reagents, and their degradation products
  • Recovered solvents and reagents carried from one process to another
  • Contaminated starting materials and intermediates from upstream suppliers

Which molecules carry more risk

Two groups deserve the most attention. The first is processes with a known history: sartans built around a tetrazole ring, such as losartan and valsartan, and molecules like metformin where dimethylamine is present. The second is APIs that contain a secondary amine in their own structure, such as duloxetine or sertraline. These can form an NDSRI, a nitrosamine of the drug molecule itself, which FDA treats separately from small nitrosamines like NDMA.

What to ask your API source for

  • The written risk assessment, covering the route, reagents, solvents including recovered solvents, water and packaging
  • Its conclusion for each nitrosamine considered, including any NDSRI specific to the molecule
  • Confirmatory test results where risk was identified, with the method and its limit of quantitation
  • The control strategy, whether routine testing or a process control that removes the risk
  • A commitment to reassess and notify you when the route, solvents or suppliers change

The drug product still needs its own assessment

A clean API doesn’t settle the question. Nitrite in excipients can nitrosate a vulnerable amine during manufacture or on stability. Your assessment has to cover the formulation too. The API source’s job is to give you an honest starting point.

How Yog Pharma handles it

The manufacturer’s nitrosamine risk assessment is part of every qualification package we send. Where the molecule or the route carries known risk, we provide confirmatory test data with it, and we pass on any reassessment when the source changes its process.

Sources

Written by Yog Pharma for buyers and quality teams. It is general information, not regulatory advice; check the current version of each source before you rely on it in a filing.